Oncolytics Biotech Inc. (ONCY)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Oncolytics Biotech Statistics
Share Statistics
Oncolytics Biotech has 77.07M shares outstanding. The number of shares has increased by 2.19% in one year.
Shares Outstanding | 77.07M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 0.11% |
Owned by Institutions (%) | n/a |
Shares Floating | 76.02M |
Failed to Deliver (FTD) Shares | 587 |
FTD / Avg. Volume | 0.06% |
Short Selling Information
The latest short interest is 2.81M, so 3.65% of the outstanding shares have been sold short.
Short Interest | 2.81M |
Short % of Shares Out | 3.65% |
Short % of Float | 3.7% |
Short Ratio (days to cover) | 3.51 |
Valuation Ratios
The PE ratio is -4.26 and the forward PE ratio is -3.73.
PE Ratio | -4.26 |
Forward PE | -3.73 |
PS Ratio | 0 |
Forward PS | 3.8 |
PB Ratio | 4.29 |
P/FCF Ratio | -4.15 |
PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Oncolytics Biotech Inc..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.01, with a Debt / Equity ratio of 0.02.
Current Ratio | 9.01 |
Quick Ratio | 9.01 |
Debt / Equity | 0.02 |
Total Debt / Capitalization | 1.51 |
Cash Flow / Debt | -67.25 |
Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.01% and return on capital (ROIC) is -121.17%.
Return on Equity (ROE) | -1.01% |
Return on Assets (ROA) | -0.71% |
Return on Capital (ROIC) | -121.17% |
Revenue Per Employee | 0 |
Profits Per Employee | -956.97K |
Employee Count | 29 |
Asset Turnover | 0 |
Inventory Turnover | 0 |
Taxes
Income Tax | 97.00K |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -34.71% in the last 52 weeks. The beta is 1.51, so Oncolytics Biotech 's price volatility has been higher than the market average.
Beta | 1.51 |
52-Week Price Change | -34.71% |
50-Day Moving Average | 0.93 |
200-Day Moving Average | 1.03 |
Relative Strength Index (RSI) | 38.04 |
Average Volume (20 Days) | 1.02M |
Income Statement
Revenue | n/a |
Gross Profit | -403.00K |
Operating Income | -33.79M |
Net Income | -27.75M |
EBITDA | -33.71M |
EBIT | n/a |
Earnings Per Share (EPS) | -0.41 |
Balance Sheet
The company has 34.91M in cash and 423.00K in debt, giving a net cash position of 34.49M.
Cash & Cash Equivalents | 34.91M |
Total Debt | 423.00K |
Net Cash | 34.49M |
Retained Earnings | -446.00M |
Total Assets | 24.26M |
Working Capital | 15.25M |
Cash Flow
In the last 12 months, operating cash flow was -28.45M and capital expenditures -8.00K, giving a free cash flow of -28.46M.
Operating Cash Flow | -28.45M |
Capital Expenditures | -8.00K |
Free Cash Flow | -28.46M |
FCF Per Share | -0.42 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
ONCY does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -51.9% |
FCF Yield | -46.55% |
Analyst Forecast
The average price target for ONCY is $4, which is 406.3% higher than the current price. The consensus rating is "Buy".
Price Target | $4 |
Price Target Difference | 406.3% |
Analyst Consensus | Buy |
Analyst Count | 2 |
Stock Splits
The last stock split was on May 25, 2018. It was a backward split with a ratio of 2:19.
Last Split Date | May 25, 2018 |
Split Type | backward |
Split Ratio | 2:19 |
Scores
Altman Z-Score | -28.63 |
Piotroski F-Score | 1 |